The case is described of a 61-year-old male who pre 
INTRODUCTION
Cushing's syndrome can be defined as the symptoms and signs associated with prolonged exposure to inap¬ propriately increased plasma corticosteroid concen¬ trations. Whilst the majority of patients suffering from Cushing's syndrome have a basophil adenoma of the pituitary secreting adrenocorticotrophin (ACTH) , in about 20% of cases the syndrome results from secretion of ACTH from a wide variety of nonpituitary tumours (Howlett, Drury, Perry et al. 1987 ). Although it has been shown that corticotrophinreleasing factor can stimulate the release of ACTH in man (Grossman, Perry, Schally et al. 1982) , there is as yet no direct evidence for the involvement of CRF-41 in the genesis or maintenance of Cushing's syndrome. Corticotrophin-releasing factor-like activity has been reported in a number of tumours not associated with Cushing's syndrome (Yamamoto, Hirata, Matsukura et al. 1976; Suda, Demura, Demura et al. 1977; Kirkland, Lumsden & Ellison, 1984; Suda, Tomori, Tozawa et al. 1984 ) but reports relating production to Cushing's syndrome are rare. Upton & Amatruda (1971) demonstrated CRF-like bioactivity in extracts of pan¬ creatic and small-cell lung tumours, and proposed that tumour CRF-like peptides may contribute to Cushing's syndrome. Corticotrophin-releasing factor¬ like bioactivity has been found in blood draining a medullary thyroid carcinoma (Birkenhager, Upton, Seldenrath et al. 1976 ) and a nephroblastoma (Hashimoto, Takahara, Ogawa et al. 1980) in patients whose Cushing's syndrome was cured by tumour excision. In all of these cases, however, precise charac¬ terization of this CRF-like bioactivity was limited by the non-availability of purified standard and it is now known that tumour peptides other than CRF-41, such as bombesin (Howlett, Price, Hale et al. 1985) , may stimulate the release of ACTH. A more recent study (Carey, Varma, Drake et al. 1984) (Coates, 1985) using primary antisera raised against synthetic ovine (o) CRF-41, and the human forms of ACTH(l-39), N- immunoreactivity of 1-3 ±0-7 (three dilutions; Text- fig. 4 ).
Tumour CRF-41 incubated with antiserum lost 72% of its ACTH-releasing potential. (Rees & Ratcliffe, 1974) . However, because tumours may con¬ tain CRF-41 and ACTH and yet not be associated with Cushing's syndrome (Bloomfield, Holdaway, Corrin et al. 1977; Suda et al. 1984) (Yamamoto et al. 1976) 
